On May 13, 2024, Reneo Pharmaceuticals, Inc. and OnKure, Inc., a privately-held, clinical-stage biopharmaceutical company focused on the development of novel precision medicines in oncology, announced that they have entered into a definitive merger agreement to combine the companies in an all-stock transaction. The combined company will focus on advancing OnKure’s pipeline candidates targeting oncogenic mutations in phosphoinositide 3-kinase alpha (PI3Kα), including its lead program OKI-219, which is currently in a Phase 1 clinical trial for the treatment of solid tumors. Upon completion of the transaction, the combined company is expected to operate under the name OnKure Therapeutics, Inc., and trade on the Nasdaq Global Market under the ticker symbol “OKUR.” The merger is expected to close in 2024.

Wilson Sonsini Goodrich & Rosati advised Reneo Pharmaceuticals on IP matters related to the transaction. The Wilson Sonsini team was led by Mike Hostetler, Valentin Zunic, and Tyler Baguley.

For more information, please see the press release.